$0.12
-0.02 (-15.69%)
Open$0.15
Previous Close$0.14
Day High$0.15
Day Low$0.10
52W High$14.71
52W Low—
Volume—
Avg Volume48.1K
Market Cap1.42M
P/E Ratio—
EPS$-9.39
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+29,350.8% upside
Current
$0.12
$0.12
Target
$35.93
$35.93
$28.98
$35.93 avg
$50.96
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.73M | 1.55M | 1.36M |
| Net Income | -107,722,981 | 56.6K | 59.8K |
| Profit Margin | -3,951.9% | 3.7% | 4.4% |
| EBITDA | -100,826,423 | 150.2K | 130.3K |
| Free Cash Flow | — | 63.5K | 61.7K |
| Rev Growth | — | -6.9% | +10.8% |
| Debt/Equity | — | 0.70 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |